# Rh-Endostatin (Endostar®) Continuous Intravenous Infusion

> **NCT03706703** · PHASE2 · UNKNOWN · sponsor: **Affiliated Cancer Hospital & Institute of Guangzhou Medical University** · enrollment: 50 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Endostar
- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT03706703
- **Lead sponsor:** Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2020-04-01
- **Final completion:** 2020-09-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03706703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03706703, "Rh-Endostatin (Endostar®) Continuous Intravenous Infusion". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03706703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*